WELCOME LETTER FACULTY

on New Drugs (and New Concepts) 5 International Meetingth

in Breast Cancer

ROME, NOVEMBER 9-10, 2017Regina Elena National Cancer InstituteBastianelli Congress Centre

PRESIDENT: Francesco Cognetti

V. Adamo, Messina (Italy)

G. Arpino, Naples (Italy)

A. Bardia, Boston (USA)

G. Bianchini, Bergamo (Italy)

C. Boni, Reggio Emilia (Italy)

C. Botti, Rome (Italy)

E. Bria, Verona (Italy)

P. Bruzzi, Genoa (Italy)

R.T. Chlebowski, Los Angeles (USA)

S. Cinieri, Brindisi (Italy)

F. Cognetti, Rome (Italy)

P. Conte, Padua (Italy)

M. Cristofanilli, Chicago (USA)

J. Crown, Dublin (Ireland)

G. Curigliano, Milan (Italy)

R. Danesi, Pisa (Italy)

A. De Censi, Genoa (Italy)

M. De Laurentiis, Naples (Italy)

S. De Placido, Naples (Italy)

L. Del Mastro, Genoa (Italy)

A. Di Leo, Prato (Italy)

M.J. Duffy, Dublin (Ireland)

A. Fabi, Rome (Italy)

G. Ferretti, Rome (Italy)

R.S. Finn, Los Angeles (USA)

C. Fontanella, Aviano (Italy)

A. Gennari, Genoa (Italy)

P. Giacomini, Rome (Italy)

S. Gori, Negrar-VR (Italy)

V. Guarneri, Padua (Italy)

A. Howell, Manchester (United Kingdom)

M. Lambertini, Genoa (Italy)

C.L. Loprinzi, Rochester (USA)

V. Lorusso, Bari (Italy)

R. Masetti,  Rome (Italy)

D.C. McKenzie, Vancouver (Canada)

G. Mustacchi, Trieste (Italy)

G. Naso, Rome (Italy)

C. Nisticò, Rome (Italy)

E. Perez, San Francisco (USA)

P. Pronzato, Genoa (Italy)

F. Puglisi, Udine (Italy)

L.M. Repetto, Rome (Italy)

F. Roila, Perugia (Italy)

V. Sacchini, Milan (Italy)

D. Santini, Rome (Italy)

F. Scaldaferri, Rome (Italy)

M. Scaltriti, New York (USA)

D.B. Solit, New York (USA)

U. Tirelli, Aviano (Italy)

C. Tondini, Bergamo (Italy)

C.J. Twelves, Leeds (United Kingdom)

S. Vella, Rome (Italy)

K. Willard-Gallo, Brussels (Belgium)

WITH AN UNRESTRICTED EDUCATIONAL GRANT OF

PRINCIPAL SPONSORS

MAJOR SPONSORS

SPONSORS

Dear Friends and Colleagues,

it is with pleasure that I welcome you to Rome for the 5th International Meeting on New Drugs (and New Concepts) in Breast Cancer, bringing together clinicians, mainly medical oncologists, and researchers including this year a substantial translational research component. The issues enlisted in this preliminary program, in particular including data from clinical trials stemming from that original basic research, demonstrate how the translation of basic research into practical clinical tools is particularly active in this disease.

The program has been designed in the pursuit of excellence and, as usually, all lectures will be presented by an international distinguished outstanding faculty who will report all their experiences and developments.

I look forward to joining you and I also hope you can enjoy a unique and pleasant stay in our wonderful City. Francesco Cognetti

AIM Education - Provider n. 93Via G. Ripamonti, 129 - 20141 Milan, ItalyPh. +39 02 56601.1 - Fax +39 02 70048585cme@aimgroup.eu - www.aimeducation.it

AIM Group International

Rome OfficeVia Flaminia, 1068 - 00189 RomePh. +39 06 33053.1 - Fax +39 06 33053249breastcancer2017@aimgroup.euhttp://web.aimgroupinternational.com/2017/breastcancer

CME PROVIDER ORGANIZING SECRETARIAT

Under the patronage of

CONGRESS VENUE AND GENERAL INFORMATION

Meeting VenueRegina Elena National Cancer Institute – Raffaele Bastianelli Congress CentreVia Fermo Ognibene, 23 – 00144 Rome

LanguageThe official language of the Congress is English. Simultaneous translation will not be provided.

Certicate of attendanceCertificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

ECM - Educazione Continua in medicina - for Italian delegates onlyL’evento è stato accreditato presso la Commissione Nazionale per la Formazione Continua con Obiettivo Formativo di Processo: integrazione interprofessionale e multiprofessionale, interistituzionale (8) per la Figura Professionale FARMACISTA con specializzazione nelle seguenti discipline FARMACIA OSPEDALIERA; FARMACIA TERRITORIALE; per la Figura Professionale BIOLOGO con specializzazione nelle seguenti discipline BIOLOGO; per la Figura Professionale MEDICO CHIRURGO con specializzazione nelle seguenti discipline ONCOLOGIA; RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; ANATOMIA PATOLOGICA; RADIODIAGNOSTICA; MEDICINA GENERALE (MEDICI DI FAMIGLIA); per un numero massimo di n. 200 partecipanti. Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette. L’EVENTO HA OTTENUTO NR. 8,4 CREDITI FORMATIVI – ID ECM: 93-204540 - ED.1

LOCAL SCIENTIFIC COORDINATOR

Alessandra Fabi

LOCAL SCIENTIFIC COMMITTEE

Daniele AlesiniSimona GasparroPaola Malaguti

SCIENTIFIC COMMITTEE

P. Conte (Padua, I)M. De Laurentiis (Naples, I)S. De Placido (Naples, I)L. Del Mastro (Genoa, I)A. Di Leo (Prato, I)S. Gori (Negrar-VR, I)P. Pronzato (Genoa, I)

• Registration Fee € 183,00 (VAT 22% included) • Registration for doctors of Regina Elena National Cancer Institute FREE • Post graduate students FREE

The registration fee entitles delegates to the following: • entry to scientific sessions • 1 coffee break and 1 buffet lunch on November 9 and 10, 2017 • CME credits • congress material • certificate of attendance

REGISTRATION INFORMATION

09.00 Lecture The tumor microenvironment in breast cancer growth and progression (A. Howell)

1ST SESSION

HER2 POSITIVE TUMORS Chairmen: F. Puglisi, C. Tondini

09.20 New biology concepts (G. Curigliano)09.40 Optimizing neoadjuvant and adjuvant treatment (G. Curigliano) 10.00 When do you add an endocrine drug to the Her2 dual blockade? (G. Arpino)10.20 Treatment duration of HER2-directed agents in metastatic disease (E. Perez) 10.40 Drug resistance: mechanism and clinical results (M. Scaltriti) 11.00 The use of biosimilars (R. Danesi)

11.20 Coffee Break

2ND SESSION

LUMINAL TUMORSChairmen: C. Botti, S. Gori

11.30 The intestinal microbiome (F. Scaldaferri)11.50 CD4/6 inhibitors: the role in the adjuvant/neoadjuvant setting (M. Cristofanilli)12.10 New PI3K inhibitors (G. Curigliano)

3RD SESSION

TRIPLE NEGATIVEChairmen: G. Mustacchi, G. Naso

12.30 Lecture Insights into the biology: new molecular classification for identifying immuno therapeutics targets (K. Willard - Gallo)12.50 New Developments in the Treatment of advanced diseases and biomarkers evidence (M.J. Duffy) 13.10 Neo/adjuvant systemic therapy today (M. Cristofanilli)

13.30 Lunch

4TH SESSION

BRCA AND NEW OPINIONS Chairmen: S. Cinieri, L. Del Mastro

Presenting: R. Masetti 14.00 Surgical update in patients with early disease and BRCA mutation (V. Sacchini)14.20 Novel drugs and new trials in BRCA mutated patients (J. Crown)14.40 Fertility and BRCA mutation (M. Lambertini)

5TH SESSION

IMMUNOSYSTEM AND IMMUNOTHERAPYChairmen: E. Bria, S. De Placido

15.00 Lecture Immunotherapy: what we still need to know? (E. Perez) 15.20 New immunotargets in breast cancer (G. Bianchini)15.40 The combination with nanoparticle molecules (M. De Laurentiis)

16.00 Discussion

6TH SESSION

NEW CONCEPTSChairmen: C. Boni, E. Bria

16.10 From phase I-III to new clinical trials methodologies in breast cancer (P. Bruzzi) 16.30 Trials on druggable mutations, regulatory implications (S. Vella)

Presenting: P. Giacomini 16.50 Lecture Precision medicine in breast cancer today (D.B. Solit)

17.10 Discussion

Presenting: F. Cognetti Lecture09.00 Breast cancer chemo-prevention (A. De Censi)

7TH SESSION

SUPPORTIVE CARE AND LIFESTYLE Chairmen: V. Adamo, C. Nisticò, F. Roila

09.20 Toxicity induced by therapy: the new profile of the oncologist (D. Santini)

THURSDAY, NOVEMBER 9

FRIDAY, NOVEMBER 10

09.40 Muscoloskeletal symptoms induced by aromatase inhibitors: new therapeutic approach (C.L. Loprinzi) 10.00 Low-fat diet: is it really a predictor for the best outcome? (R.T. Chlebowski) 10.20 Physical exercise and breast cancer: risk correlation to subtype and therapeutic effect (D.C. McKenzie)

Presenting: P. Pronzato10.40 Lecture Adjuvant therapy in HER2 positive early breast cancer: for whom? How long? With what? (P. Conte)

11.00 Coffee Break

8TH SESSION

EVOLVING MOLECULESChairmen: G. Ferretti, V. Guarneri

11.10 Etirinotecal pegol: in which position in the future clinical choice? (C.J. Twelves) 11.30 Trop-2: potential target for antibody-drug conjugates (A. Bardia)

9TH SESSION

HORMONAL THERAPY AND NOVEL DISCOVERIES IN DRUG RESISTANCESChairmen: A. Fabi, V. Lorusso

11.50 Lecture Mechanism and clinical results in ER positive patients (A. Di Leo)12.10 New selective estrogen receptor antagonist (R.S. Finn)12.30 Lecture Clinical utility of multigene assays and outcome of disease (M. De Laurentiis)

10TH SESSION

AGE AND BREAST CANCERChairmen: A. Gennari, U. Tirelli

12.50 Evaluation and treatment of older patients (in early stage) (L.M. Repetto)13.10 The treatment of Metastatic disease in elderly patients, light and shadow (C. Fontanella)

13.30 Discussion and Conclusions

14.00 Lunch